

DRG®

Afamin ELISA



Afamin ELISA

AVAILABLE!

EIA-5085

Applications:

Afamin is a potential biomarker for ovarian cancer and testicular cancer

Principle of the test:

Solid phase **Enzyme-Linked Immunosorbent Assay (ELISA)** based on the competitive principle

Specimen:

Serum or EDTA Plasma or Heparin Plasma or Follicle Fluid or CSF

Assay characteristics:

- **Total assay time:** ~ 2.5 h
- **Detection limit:** 0.01 ng/mL
- **Precision:**
Intra assay: 3.4 %
Inter assay: 5.0 %



High Specificity and Sensitivity of Afamin for Ovarian Cancer (OC)

- Screening assay for OC with sufficient positive predictive value: specificity and sensitivity must be > 95%
- Low specificity of CA125: elevated in many physiological, benign and malignant conditions (menstruation, pregnancy, endometriosis, pancreatic, lung, breast, colorectal cancer)
- 400 patients and controls
- - Afamin: specificity 95%, sensitivity 96%
- - CA 125: specificity: 55%, sensitivity 84%

Summary Afamin – Ovarian Cancer

- Significantly reduced Afamin plasma concentrations in pre-operative OC patients normalize after tumor removal – decrease again at tumor recurrence
- Highly improved specificity and sensitivity of DRG's assay as compared with conventional markers

Summary Afamin – Testicular Cancer

- Significantly reduced Afamin plasma concentrations in pre-operative TC patients – normalize after tumor removal
- High specificity and sensitivity
- Predictive for all species of TC – replaces at least 2 conventional markers



USA Headquarters
DRG International, Inc.
1167 U.S. Highway 22 East
Mountainside, N.J. 07092 USA
corp@drg-international.com
www.drg-international.com



Germany
DRG Instruments GmbH
Frauenbergstraße 18
D-35039 Marburg
drg@drg-diagnostics.de
www.drg-diagnostics.de

09/09/15